Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AbbVie, Parkinson's disease
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease
AbbVie Inc (NYSE:ABBV) released topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson’s disease. Tavapadon is an investigational D1/D5 dopamine receptor partial agonist being studied as a once-daily treatment for Parkinson’s disease.
AbbVie's dopamine-focused Parkinson's treatment reduces disease burden in phase 3 trial
AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That trial is testing the drug as a flexible-dose monotherapy.
AbbVie Parkinson's disease therapy hits main goal in late-stage trial
AbbVie (ABBV) said its Phase 3 trial TEMPO-1 for experimental therapy Tavapadon reached main goal in Parkinson's disease. Read more here.
AbbVie's Parkinson's disease drug meets main goal in late-stage trial
AbbVie's drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease, the company said on Thursday. Patients showed a statistically significant improvement when two fixed doses of the drug,
AbbVie: Tavapadon Meets Primary, Secondary Endpoints In Phase 3 Trial In Early Parkinson's Disease
Drugmaker AbbVie (ABBV) announced Thursday positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a
AbbVie: Tavapadon Meets Key Endpoints in Phase 3 Parkinson's Study
AbbVie on Thursday said a late-stage study of its recently acquired tavapadon drug candidate for the neurodegenerative disorder Parkinson's disease hit its key goals. AbbVie said tavapadon met the primary endpoint in the pivotal Phase 3 fixed-dose monotherapy trial,
16h
AbbVie Inc. stock rises Thursday, still underperforms market
Shares of AbbVie Inc. ABBV inched 0.33% higher to $191.90 Thursday, on what proved to be an all-around great trading session ...
1d
Abbvie Worker Advances Suit Over Family Medical History Queries
Abbvie Inc. failed to defeat a proposed class action by a Chicago-area technician who says he and other workers were ...
bovnews
1d
ABBV’s Latest Twist: What’s Fueling the Unexpected Shifts in AbbVie Inc’s Stock Price?
AbbVie Inc (ABBV) stock saw a decline, ending the day at $193.51 which represents a decrease of $-0.32 or -0.17% from the prior close of $193.83. The stock opened at $192.95 and touched a low of $191.
2d
AbbVie Inc. stock outperforms competitors despite losses on the day
AbbVie Inc. closed $6.44 short of its 52-week high ($199.95), which the company achieved on September 3rd.
clinicaltrialsarena
1d
AbbVie’s RINVOQ shows promise in two Phase III atopic dermatitis trials
AbbVie has revealed positive data from a post-hoc analysis of Phase III trials of RINVOQ in treating atopic dermatitis (AD).
1d
Bristol Myers Squibb Vs. AbbVie Stock
Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...
Hosted on MSN
3d
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...
9d
AbbVie Inc. (NYSE:ABBV) is largely controlled by institutional shareholders who own 73% of the company
If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...
1d
AbbVie: Upadacitinib Phase 3 Trials' Post-hoc Analysis Show Positive Results In Atopic Dermatitis
Drug maker AbbVie (ABBV) announced Wednesday positive results from a new post-hoc analysis of Phase 3 Studies, demonstrating efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Dow Jones Industrial Average
Parkinson's disease
Atopic dermatitis
Feedback